TY - JOUR
TI - Serum irisin concentrations in lean adolescents with polycystic ovary syndrome
AU - Bacopoulou, F.
AU - Athanasopoulos, N.
AU - Efthymiou, V.
AU - Mantzou, A.
AU - Aravantinos, L.
AU - Vlahopoulos, S.
AU - Deligeoroglou, E.
JO - Clinical Endocrinology
PY - 2018
VL - 88
TODO - 4
SP - 585-591
PB - Wiley-Blackwell Publishing Ltd
SN - 0300-0664, 1365-2265
TODO - 10.1111/cen.13555
TODO - androgen;  androstenedione;  estradiol;  follitropin;  glucose;  hydroxyprogesterone;  insulin;  irisin;  luteinizing hormone;  prasterone sulfate;  testosterone;  fibronectin;  FNDC5 protein, human, adolescent;  adult;  age;  androstenedione blood level;  Article;  body mass;  clinical article;  controlled study;  cross-sectional study;  disease association;  estradiol blood level;  female;  follitropin blood level;  glucose blood level;  homeostasis model assessment;  hormone blood level;  human;  lean body weight;  luteinizing hormone blood level;  ovary polycystic disease;  priority journal;  progesterone blood level;  Quantitative Insulin Sensitivity Check Index;  testosterone blood level;  blood;  case control study;  ovary polycystic disease;  young adult, Adolescent;  Case-Control Studies;  Cross-Sectional Studies;  Female;  Fibronectins;  Humans;  Polycystic Ovary Syndrome;  Sedentary Behavior;  Young Adult
TODO - Objective: To explore differences in irisin concentrations between lean adolescents with PCOS and age- and body mass index (BMI)-matched controls and examine the associations of irisin with core features of the syndrome. Design: Cross-sectional study. Patients: Lean females with PCOS, aged 13-21 years. Measurements: Physical, hormonal and sonographic assessment. Irisin concentrations were measured with ELISA. Results: Participants included in total 39 sedentary females (mean ± SD; age 17.3 ± 2.1 years, BMI 20.7 ± 1.3 Kg/m2), 23 adolescents with PCOS and 16 controls. Adolescents with PCOS compared to controls had significantly elevated concentrations of fasting serum irisin (mean ± SD; PCOS, 1.7 ± 1.0 μg/mL vs controls, 1.0 ± 0.4 μg/mL; P =.007), luteinizing hormone (LH), oestradiol, testosterone, Δ4-androstenedione, 17-hydroxyprogesterone, glucose, as well as free androgen index, Ferriman-Gallwey score and mean ovarian volume (MOV). For the total sample, circulating irisin was positively correlated with MOV (r =.332, P =.041), glucose (r =.428, P =.007), insulin (rs =.369, P =.021) and HOMA-IR (rs =.422, P =.007) and negatively correlated with QUICKI (r = −.329, P =.041). Follicle-stimulating hormone (B = 0.295, Beta =.342, P =.042) and MOV (B = 0.182, Beta = 0.821, P =.001) were positive predictors, and LH (B = −0.108, Beta = −0.523, P =.010) and testosterone (B = −0.431, Beta = −0.457, P =.032) were negative predictors of irisin concentrations, whereas irisin positively predicted fasting glucose (B = 0.262, Beta = 0.428, P =.007). In the PCOS group, irisin concentrations were positively correlated with HOMA-IR (rs =.416, P =.048) but negatively correlated with LH (rs = −.499, P =.015), testosterone (r = −.585, P =.003), free androgen index (r = −.426, P =.048) and Ferriman-Gallwey score (r = −.533, P =.015). Conclusions: Irisin was associated with the adolescents' metabolic and reproductive characteristics and the hyperandrogenic phenotype of the syndrome. Much research is needed to ascertain mechanisms of elevated serum irisin in adolescent PCOS. © 2018 John Wiley & Sons Ltd
ER -